We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00245622
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : March 10, 2014
Sponsor:
Information provided by (Responsible Party):
Opexa Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 2008
  Study Completion Date : September 2008
  Certification or Request for Extension to Delay Results Submission: June 27, 2011
Publications:
Fox E, Markowitz C, Cohan S, Wynn D. TERMS Trial TCV Secondary Analysis of Clinical and Immunological Outcoms in Patients with Relapsing Remitting MS. Poster presentation P06.132 at the 61st Annual Meeting of the American Academy of Neurology (AAN) on 01 May 2009.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):